ポスト
Seqirus IncによるH5N1インフルエンザワクチン、AUDENZ™がFDAの承認を取得 AUDENZ is approved for use in persons 6 months of age and older at increased risk of exposure to the influenza A virus H5N1 subtype contained in the vaccine. fda.gov/vaccines-blood…
メニューを開くSeqirus IncによるH5N1インフルエンザワクチン、AUDENZ™がFDAの承認を取得 AUDENZ is approved for use in persons 6 months of age and older at increased risk of exposure to the influenza A virus H5N1 subtype contained in the vaccine. fda.gov/vaccines-blood…
メニューを開く